AIM Vaccine Co., Ltd. announced that the pre-application for clinical trials for the Group's absorbed tetanus vaccine has been submitted recently. The research and development of the vaccine is in line with the Company's strategic layout in product research and development and is an important step to realize the Company's research and development of multidisease and multivalent products, which will further improve the Company's product pipelines, help the Company consolidate its industry position in the field of vaccines not covered by the immunization programs (Class II vaccine) in China, and contribute to the sustainable development of the Company's vaccine business. Tetanus is an extremely serious and potentially fatal disease, and tetanus vaccination is currently the most cost-effective and effective measure to prevent it.

In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis - HIB combined vaccine (the " Tetravaccine "), and is expected to successively submit clinical trial applications for Tetravaccine and its component vaccines from 2024. The Tetravaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and Haemophilus Influenzae type b, and has the advantages of reducing the number of vaccinations for infants and young children, and enhancing the vaccination compliance of parents, infants and young children. Multidisease vaccine is the development trend of the industry, which provides strong support for the strengthening of the Company's core competitiveness, enhancement of the Company's market position, and the Company's sustainable and steady development.